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about previous excisions of skin lesions with 81% of them 
asking for a histopathological slide review of previous biop-
sies. Half of the participants checked for a possible vitiligo 
phenomenon that may explain regression of the primary le-
sion.  BRAF, cKIT, and  GNAQ mutations were screened by 32% 
of participants. The majority of participants (76%) applied 
the same treatment protocols for MUP as patients with 
known primary melanomas of the same AJCC stage.  Conclu-
sion: Strong heterogeneity was found between physicians 
dealing with MUP. Thus, a consensus document should be 
strongly encouraged.  © 2017 S. Karger AG, Basel 
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 Abstract 
 Background: How to deal with melanoma of unknown pri-
mary (MUP) origin is a debated topic in the literature.  Objec-
tive: We performed a worldwide survey to inquire what clin-
ical and investigational workup is performed as well as the 
physicians’ perception of this disease.  Methods: A question-
naire was sent via mail to clinicians involved in melanoma 
care from December 2015 to April 2016 using the Interna-
tional Dermoscopy Society website.  Results: 119 physicians 
from 47 different countries answered the questionnaire. The 
most reported examination was skin examination followed 
by CT and/or PET scans. All the participants declared asking 
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 Introduction 
 Melanoma of unknown primary (MUP) or occult pri-
mary melanoma represents only a minority of melanoma 
cases, occurring in almost 3% of patients with histologi-
cally confirmed metastatic melanoma in either lymph 
nodes, (sub)cutaneous tissue, or visceral sites  [1] . The di-
agnosis of MUP is commonly based on the impossibility 
to identify a primary cutaneous, ocular or mucosal lesion 
throughout physical examination and revision of previ-
ous excisions  [2] .
 In 1963, Das Gupta et al.  [3] first described diagnostic 
criteria for MUP excluding from this category patients 
who did not receive complete physical examination, in-
cluding anus/genitalia and ophthalmological visit, pa-
tients with evidence of previous orbital enucleation, pa-
tients who underwent surgical or nonsurgical procedures, 
without histological documentation, for a mole, birth-
mark, freckle, chronic paronychia, or skin blemish, in 
particular in cases of nodal involvement and presence of 
a scar in the skin area drained by the lymphatic basin.
 The majority of MUP cases are nodal (60%), with the 
axilla, neck and groin representing the most frequent 
sites; the remaining cases involve the (sub)cutaneous tis-
sue and various visceral sites  [4] .
 Concerning the origin, MUP should probably be con-
sidered a heterogeneous entity, comprising cases with ful-
ly regressed primary lesions, cases of internal or nodal 
primary melanomas and cases where the primary tumor 
had been treated with nonsurgical procedures or excised 
without proper histological confirmation  [5] .
 The management and prognosis of MUP is a debated 
topic in the literature. Despite evidence reporting a similar 
or more favorable prognosis compared to melanomas of 
known origin according to stage, physicians are usually 
more worried when dealing with MUPs, and different fol-
low-up approaches are used  [6] . Moreover, there is a lack 
of consensus regarding the investigations that should be 
performed in searching for a potential primary melanoma.
 The current survey aimed to investigate which type of 
investigations is currently performed to search for the 
melanoma primary in MUP.
 Materials and Methods 
 For further details, see the supplementary materials (for all on-
line suppl. material, see www.karger.com/doi/10.1159/000453592) 
( Fig. 1 ).
 Results 
 In all, 119 physicians from 47 different countries re-
turned the questionnaire (men, 52%; mean age, 45.5 
years; range, 26–72 years). Worldwide distribution of 
participants involved all 5 continents (75 Europe, 17 Asia, 
16 America, 7 Oceania, and 4 Africa). Fifty-five (46%) of 
the participants worked in a university hospital, 24 (20%) 
in a district hospital, and 40 (34%) in private practice.
 The majority of the participants (89%) were derma-
tologists, and the others were equally distributed between 
surgeons, oncologists, and general practitioners with spe-
cial interest in dermatology.
 The mean number of new melanomas treated yearly 
by each physician was 37 ± 6.8, with 88% of the partici-
pants reporting at least 1 stage III or IV melanoma patient 
treated in the previous year.
 Half of the participants (51%) reported to have treated 
more than 1 patient with MUP in the last 5 years, while 
21% had treated at least 1 in the previous year.
 The great majority of patients with MUPs had skin 
metastases as first disease manifestation (51 cases), fol-
lowed by nodal (41), visceral (32), and mucosal metasta-
ses (14).
 The distribution of requested investigations is report-
ed in  Table 1 . The most frequent was a skin examination 
followed by CT and/or PET scans. More invasive investi-
gations such as colonoscopy and gastroscopy were not 
reported with high priority. In particular, there was a 
strong agreement (88%, κ = 0.76) between the ones sug-
gesting colonoscopy and the ones suggesting gastroscopy.
 All the participants declared asking about previous ex-
cisions of skin lesions, with 81% of them asking for a his-
topathological slide review of previous biopsies. Half of 
the participants checked for a possible vitiligo phenom-
Designing the questionnaire by C. Longo and S. Ribero
Dissemination of the questionnaire between December 2015 and
April 2016 by the channel of the International Dermoscopy Society
website: http://www.dermoscopy-ids.org 
Validation of the questionnaire among experts
 Fig. 1. Flowchart of Materials and Methods. 
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enon that may indicate regression of the primary lesion. 
 BRAF, cKIT, and  GNAQ mutations were screened by 32% 
of the participants. 
 When asked for the more suitable explanations of 
MUP, 16 reported a possible amelanotic melanoma, 52 
believed in regression of primary, 18 thought about a
misdiagnosed nevus, 13 in melanoma in lymph nodes 
and 11 in an internal primary.
 Regarding treatment, the majority of the participants 
(76%) declared to apply the same treatment protocols in 
MUP as compared to patients with known primary mela-
nomas of the same AJCC stage  [7] , 4 (3%) answered that 
they would treat the patient in a more relaxed and 24 
(21%) in a more worried fashion.
 Fifty-four (47%) participants thought that the progno-
sis of patients with MUP is worse than of those with non-
MUP, 19 (17%) that it is better and 41 (36%) that it is su-
perimposable.
 Discussion 
 Treatment of metastatic melanoma is a challenging 
topic; despite the recent progress, the majority of the pa-
tients will die in a relatively short time  [8] . MUP is by 
definition a metastatic melanoma  [1] . After Das Gupta et 
al.  [3] had first defined MUP criteria, many authors in-
vestigated the prognosis of this entity with conflicting re-
sults  [1, 9–11] .
 The American Joint Committee on Cancer 2009 mel-
anoma staging system stated to classify MUP with nodal 
or (sub)cutaneous involvement as stage III and cases 
with visceral metastasis as stage IV; however, the prog-
nostic significance of this entity was not properly speci-
fied  [7] .
 Recently, a meta-analysis  [6] of observational studies 
showed a better survival in patients with MUP compared 
to patients with known primary melanomas, according to 
stage; the authors hypothesized that the antitumor im-
mune response to MUP may lead to a better survival, as 
they considered spontaneous regression as one of the 
probable causes of MUP. It was also suggested that the 
same therapeutic approach should be followed for both 
of these entities  [12] . Furthermore, histological regres-
sion has been described as a potential favorable feature of 
melanoma as it probably reflects an activation of the im-
mune system  [13] . On the other hand, discordant data are 
reported regarding the survival of patients with complete 
regressed primary cutaneous melanoma  [14] .
 In spite of this, the majority of responders in this sur-
vey considered survival of MUP worse than for known 
primaries, although only a minority would manage this 
entity with a more aggressive therapeutic approach.
 Concerning finding a potential primary, very few stud-
ies assessed the usefulness of clinical examination and im-
aging for detecting the primary tumor.
 In particular, Tos et al.  [15] investigated the best 
screening for MUP, concluding that skin examination, 
medical history, histopathological review of previous ex-
cisions and CT/PET for staging should be performed.
 Our results also highlight the primary role of careful 
skin examination and anamnesis for the identification 
and histopathological revision of previous skin excisions 
in MUP patients.
 Two thirds of the participants estimated that the skin 
was the most likely primary site for MUP, in agreement 
with recent studies demonstrating a similar molecular 
profile between MUP and melanomas on nonchronically 
sun-damaged skin  [16, 17] .
 One of the major concerns regarding screening for pri-
mary tumor in MUP patients is the need for a multidisci-
plinary approach. In our survey, almost half of the par-
ticipants referred MUP patients for gynecology or ear-
neck-throat examinations to look at possible melanoma 
localizations.
 This could be explained not only by the lower concern 
of a primary mucosal origin of MUP, but also by a higher 
ability of dermatologists in diagnosing mucosal melano-
mas of the mouth and genital area, thanks to dermoscopy 
 [18, 19] .
 Regarding instrumental examinations, CT and/or PET 
were largely preferred to endoscopy, probably as the for-
mer primarily have a staging role.
 Table 1.  List of clinical examinations and imaging used for MUP 
from participants in the survey (n = 107)
Examination Yes Percent
CT/PET 95 88.7
Gynecological examination 48 44.8
Ophthalmological examination 66 61.7
Rectoscopy 34 31.8
Colonoscopy 36 33.6
Gastroscopy 30 28.0
Skin examination 99 92.5
Ear-neck-throat examination 38 35.5
BRAF/KIT/GNAQ mutations 35 32.7
Documentation of previous skin biopsies 107 100
Review of histopathology for previous lesions 87 81
Check for vitiligo 53 49.5
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
ita
 d
i T
or
in
o 
   
   
   
   
   
   
   
   
   
 
13
0.
19
2.
11
9.
15
6 
- 6
/4
/2
01
7 
7:
11
:2
1 
PM
 Survey on Management of Unknown 
Primary Melanoma 
Dermatology 2016;232:704–707
DOI: 10.1159/000453592
707
 Our survey has 2 limitations: first, it is more based on 
physicians’ perception than real data from different cen-
ters; second, respondents cannot be considered totally 
representative of the International Dermoscopy Society 
membership.
 In conclusion, strong variability was found between 
physicians dealing with MUP, despite the high preva-
lence of doctors who manage treatment in stage III or
IV. A consensus document is needed in order to assist cli-
nicians in the clinical workup of a given patient with 
MUP and in defining the need for a multidisciplinary ap-
proach.
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